These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27191543)

  • 1. Ecologic Study of Meningococcal B Vaccine and Neisseria gonorrhoeae Infection, Norway.
    Whelan J; Kløvstad H; Haugen IL; Holle MR; Storsaeter J
    Emerg Infect Dis; 2016 Jun; 22(6):1137-9. PubMed ID: 27191543
    [No Abstract]   [Full Text] [Related]  

  • 2. VA-MENGOC-BC Vaccination Induces Serum and Mucosal Anti Neisseria gonorrhoeae Immune Responses and Reduces the Incidence of Gonorrhea.
    Reyes Díaz LM; Lastre González MSJB; Cuello M; Sierra-González VG; Ramos Pupo R; Lantero MI; Harandi AM; Black S; Pérez O
    Pediatr Infect Dis J; 2021 Apr; 40(4):375-381. PubMed ID: 33591079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vaccine for meningococcal B disease and gonorrhoea.
    Kirby T
    Lancet Infect Dis; 2020 Apr; 20(4):417. PubMed ID: 32222210
    [No Abstract]   [Full Text] [Related]  

  • 4. Exploitation of
    Petousis-Harris H; Radcliff FJ
    Front Immunol; 2019; 10():683. PubMed ID: 31024540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Neisseria gonorrhoeae With Meningococcal B Vaccine: A Matched Cohort Study in Southern California.
    Bruxvoort KJ; Lewnard JA; Chen LH; Tseng HF; Chang J; Veltman J; Marrazzo J; Qian L
    Clin Infect Dis; 2023 Feb; 76(3):e1341-e1349. PubMed ID: 35642527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of meningococcal group B OMV vaccines, beyond their brief.
    Petousis-Harris H
    Hum Vaccin Immunother; 2018 May; 14(5):1058-1063. PubMed ID: 29048985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol.
    Thng C; Semchenko EA; Hughes I; O'Sullivan M; Seib KL
    BMC Public Health; 2023 Mar; 23(1):607. PubMed ID: 36997957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study.
    Abara WE; Bernstein KT; Lewis FMT; Schillinger JA; Feemster K; Pathela P; Hariri S; Islam A; Eberhart M; Cheng I; Ternier A; Slutsker JS; Mbaeyi S; Madera R; Kirkcaldy RD
    Lancet Infect Dis; 2022 Jul; 22(7):1021-1029. PubMed ID: 35427490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neisseria meningitidis serogroup B vaccine development.
    Caesar NM; Myers KA; Fan X
    Microb Pathog; 2013 Apr; 57():33-40. PubMed ID: 23416222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Brief: New meningococcal serogroup B vaccination recommendations.
    Med Lett Drugs Ther; 2020 Nov; 62(1612):191-192. PubMed ID: 33443493
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluating vaccine-elicited antibody activities against
    Gray MC; Thomas KS; Lamb ER; Werner LM; Connolly KL; Jerse AE; Criss AK
    Infect Immun; 2023 Dec; 91(12):e0030923. PubMed ID: 37991382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae.
    Hadad R; Jacobsson S; Pizza M; Rappuoli R; Fredlund H; Olcén P; Unemo M
    APMIS; 2012 Sep; 120(9):750-60. PubMed ID: 22882265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Authors' response: Meningococcal vaccine antigen diversity in global databases.
    Brehony C; Hill DM; Lucidarme J; Borrow R; Maiden MC
    Euro Surveill; 2016 Apr; 21(15):. PubMed ID: 27104935
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model.
    Régnier SA; Huels J
    Hum Vaccin Immunother; 2014; 10(12):3737-45. PubMed ID: 25483706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of group B meningococcal disease by vaccination: a difficult task.
    Thomas M
    N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of the Impact of Meningococcal Serogroup C Universal Vaccination in Italy and Suggestions for the Multicomponent Serogroup B Vaccine Introduction.
    Martinelli D; Fortunato F; Cappelli MG; Cozza V; Chironna M; Prato R
    J Immunol Res; 2015; 2015():710656. PubMed ID: 26351649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neisseria gonorrhoeae vaccine development: hope on the horizon?
    Edwards JL; Jennings MP; Seib KL
    Curr Opin Infect Dis; 2018 Jun; 31(3):246-250. PubMed ID: 29601324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal B Vaccination (4CMenB) in Infants and Toddlers.
    Esposito S; Tagliabue C; Bosis S
    J Immunol Res; 2015; 2015():402381. PubMed ID: 26351647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serogroup B Meningococcal Disease Vaccine Recommendations at a University, New Jersey, USA, 2016.
    Soeters HM; Dinitz-Sklar J; Kulkarni PA; MacNeil JR; McNamara LA; Zaremski E; Chang HY; Lujan E; Granoff D; Lasky M; Montana B
    Emerg Infect Dis; 2017 May; 23(5):867-869. PubMed ID: 28418307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neisseria proteomics for antigen discovery and vaccine development.
    Christodoulides M
    Expert Rev Proteomics; 2014 Oct; 11(5):573-91. PubMed ID: 25017717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.